2 completed, 2 recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow N,N-Dimethyltryptamine: new trials by email Literature Review of N,N-Dimethyltryptamine trials Research Report on N,N-Dimethyltryptamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Psilocybin (drug) - Depression, Parkinson's Disease (PD) | Phase 2 | Recruiting | Yale University | 40 | 2026-07-10 | 2026-09-28 |
| Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression N,N-Dimethyltryptamine - Depressive Disorder, Depression, Unipolar | Phase 2 | Completed | Universidade Federal do Rio Grande do Norte | 14 | 2023-10-09 | 2024-05-08 |
| SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients SPL026, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Small Pharma Ltd | 66 | 2021-02-04 | 2024-03-27 |
Depressive Disorder, Major (2) · Depression (1) · Depressive Disorder (1) · Movement Disorders (1) · Parkinson Disease (1) · Suicidal Ideation (1) · Suicide (1)
Universidade Federal do Rio Grande do Norte (2) · Small Pharma Ltd (1) · Yale University (1)
Brazil (2) · United Kingdom (1) · United States (1)
David Erritzoe, MD (1) · Draulio Araujo, Ph.D (1) · Fabian Devlin, MD (1) · Fernanda Palhano-Fontes, Ph.D (1) · Malcolm Boyce, MD (1) · Marcelo Falchi, M.D. (1) · Sophie Holmes, PhD (1)
PMID 37086340, PMID 38274414, PMID 40258990, PMID 40337754, PMID 40484114, PMID 41699126